144 related articles for article (PubMed ID: 11936929)
1. Challenges in the development of effective peptide vaccines for cancer.
Buteau C; Markovic SN; Celis E
Mayo Clin Proc; 2002 Apr; 77(4):339-49. PubMed ID: 11936929
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
3. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
4. Melanoma peptide vaccines: from preclinical background to clinical trials.
Weber J
Curr Oncol Rep; 2000 Jan; 2(1):38-47. PubMed ID: 11122823
[TBL] [Abstract][Full Text] [Related]
5. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
6. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
7. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
8. A new era in anticancer peptide vaccines.
Perez SA; von Hofe E; Kallinteris NL; Gritzapis AD; Peoples GE; Papamichail M; Baxevanis CN
Cancer; 2010 May; 116(9):2071-80. PubMed ID: 20187092
[TBL] [Abstract][Full Text] [Related]
9. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.
Voskens CJ; Strome SE; Sewell DA
Curr Mol Med; 2009 Aug; 9(6):683-93. PubMed ID: 19689295
[TBL] [Abstract][Full Text] [Related]
10. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
[TBL] [Abstract][Full Text] [Related]
11. Mimotope vaccines for cancer immunotherapy.
Sharav T; Wiesmüller KH; Walden P
Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
[TBL] [Abstract][Full Text] [Related]
12. Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy.
Beebe M; Qin M; Moi M; Wu S; Heiati H; Walker L; Newman M; Fikes J; Ishioka GY
Hum Vaccin; 2008; 4(3):210-8. PubMed ID: 18382135
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
14. Current status and future prospects of peptide-based cancer vaccines.
Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
[TBL] [Abstract][Full Text] [Related]
15. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.
Sotirov S; Dimitrov I
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732150
[TBL] [Abstract][Full Text] [Related]
17. Peptide-Based Cancer Vaccine Strategies and Clinical Results.
Schneble E; Clifton GT; Hale DF; Peoples GE
Methods Mol Biol; 2016; 1403():797-817. PubMed ID: 27076168
[TBL] [Abstract][Full Text] [Related]
18. Immunoinformatics, molecular modeling, and cancer vaccines.
Mishra S; Sinha S
Methods Mol Biol; 2014; 1184():513-21. PubMed ID: 25048143
[TBL] [Abstract][Full Text] [Related]
19. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
[TBL] [Abstract][Full Text] [Related]
20. Guidance for peptide vaccines for the treatment of cancer.
Yamaguchi Y; Yamaue H; Okusaka T; Okuno K; Suzuki H; Fujioka T; Otsu A; Ohashi Y; Shimazawa R; Nishio K; Furuse J; Minami H; Tsunoda T; Hayashi Y; Nakamura Y;
Cancer Sci; 2014 Jul; 105(7):924-31. PubMed ID: 25040224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
